Skip to content
- Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting. Tameris M, Rozot V, Imbratta C, Geldenhuys H, Mendelsohn SC, Kany Luabeya AK, Shenje J, Tredoux N, Fisher M, Mulenga H, Bilek N, Young C, Veldsman A, Botes N, Thole J, Fritzell B, Mukherjee R, Jelsbak IM, Rodriguez E, Puentes E, Doce J, Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C, Scriba TJ, Hatherill M; MTBVAC 202 study team. EBioMedicine. 2025 Apr;114:105628. doi: 10.1016/j.ebiom.2025.105628. Epub 2025 Mar 17.
- A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. Cavaleri, M, Alves de Sousa CM, Hacker A, Higgs ES, Lumpkin MM, Maia CS, Mathur R, Fimbo AM, Reis A, Shin KS, Vaugh DW, Zhang W, Moorthy, V. Lancet Glob Health. 2025 Apr.;13(4)
- Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice. Gobat N, Slack C, Hannah S, Salzwedel J, Bladon G, Burgos JG, Purvis B, Molony-Oates B, Siegfried N, Cheah PY, Conway M, Kamuya D, Davies A, Johnson T, Tholanah M, Mugamba S, Mutengu NL, Machingaidze S, Schwartz L, Rägo L, von Harbou K. Lancet Glob Health. 2025 Apr;13:e716-31
- A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient delivery carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis. Yun JS, Kim SM, Lee JS, Jeong SH, Oh H, Son P, Kim S, Lee YR, Shin E, Ha SJ, Jung YW, Kim D, Jeong HS, Choi WI. Cell Commun Signal. 2025 Apr 1;23(1):159. doi: 10.1186/s12964-025-02105-2.
- BCG induced innate immune response heterogeneity and susceptibility to pediatric tuberculosis. Anterasian C, Gela A, Mwambene TD, Shah JA, Ivie J, Dill-McFarland KA, Hanekom WA, Kiritsy MC, Sassetti CM, Musvosvi M, Hatherill M, Scriba TJ, Hawn TR. J Immunol. 2025 Apr 2:vkae062. doi: 10.1093/jimmun/vkae062. Epub ahead of print.
- Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans. Proulx MK, Wiggins CD, Reames CJ, Wu C, Kiritsy MC, Xu P, Gallant JC, Grace PS, Fenderson BA, Smith CM, Lindestam Arlehamn CS, Alter G, Lauffenburger DA, Sassetti CM. J Exp Med. 2025 Apr 7. doi: 10.1084/jem.20241760. Epub ahead of print.
- Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes. Simonson AW, Zeppa JJ, Bucsan AN, Chao MC, Pokkali S, Hopkins F, Chase MR, Vickers AJ, Sutton MS, Winchell CG, Myers AJ, Ameel CL, Kelly RJ, Krouse B, Hood LE, Li J, Lehman CC, Kamath M, Tomko J, Rodgers MA, Donlan R, Chishti H, Borish HJ, Klein E, Scanga CA, Fortune SM, Lin PL, Maiello P, Roederer M, Darrah PA, Seder RA, Flynn JL. J Exp Med. 2025 Apr 7;222(4):e20241571. doi: 10.1084/jem.20241571. Epub 2025 Feb 6.
- Early secretory antigen target of 6-kDa of Mycobacterium tuberculosis inhibits macrophage apoptosis and host defense via TLR2. Zhang L, Fang F, Liu D, Xia G, Feng T, Lv J, Qi J, Li T, Liu H, Xu T, Wu F, Song C, Li W, Wang X, Chang X, Wang H, Wang T, Qian Z. Respir Res. 2025 Apr 9;26(1):131. doi: 10.1186/s12931-025-03210-z.
- Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial. Luabeya AKK, Rozot V, Imbratta C, Ratangee F, Shenje J, Tameris M, Mendelsohn SC, Geldenhuys H, Fisher M, Musvosvi M, Young C, Mulenga H, Bilek N, Mabwe S, Jelsbak IM, Rodríguez E, Puentes E, Doce J, Aguilo N, Martin C, Pillay C, Tait D, Russell M, Van Der Merve A, Rutkowski K, Hunt D, Ginsberg A, Scriba TJ, Hatherill M; A050 team. Lancet Glob Health. 2025 Apr 15:S2214-109X(25)00046-4. doi: 10.1016/S2214-109X(25)00046-4. Epub ahead of print.
- Effect of Bacillus Calmette-Guérin vaccination against Mycobacterium tuberculosis infection in children: an updated systematic review and meta-analysis. Cai S, Luo Q, Zhou G, Guo X, Dong Y, Chen H, Luo S, He J, Xia Y, Li H, Zhou Y, Song C. Int J Infect Dis. 2025 Apr 16:107909. doi: 10.1016/j.ijid.2025.107909. Epub ahead of print.
- Bioinformatics analysis, immunogenicity, and therapeutic efficacy evaluation of a novel multi-stage, multi-epitope DNA vaccine for tuberculosis. Guo J, Jia Z, Yang Y, Wang N, Xue Y, Xiao L, Wang F, Wang L, Wang X, Liu Y, Wang J, Gong W, Zhao H, Liang Y, Wu X. Int Immunopharmacol. 2025 Apr 16;152:114415. doi: 10.1016/j.intimp.2025.114415. Epub 2025 Mar 13.
- Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant. Larsen SE, Rais M, Reese VA, Ferede D, Pecor T, Kaur S, Nag D, Smytheman T, Gray SA, Carter D, Baldwin SL, Coler RN. Immunohorizons. 2025 Apr 26;9(6):vlaf014. doi: 10.1093/immhor/vlaf014.
